[Ip-health] New Tufts study on R&D costs
ahollis at ucalgary.ca
Fri Nov 14 09:57:50 PST 2014
Biologics are already in the $1.7bn range. So given that they will be using data from a very low productivity period, when new approvals were dragging and budgets were relatively high, I predict precisely $2.17bn
Current FDA approvals are sharply up, but I guess the most recent years’ data will not be included.
Professor of Economics
University of Calgary
ahollis at ucalgary.ca <mailto:ahollis at ucalgary.ca>
+1 403 220 5861
Incentives for Global Health
On Nov 14, 2014, at 10:41 AM, Gaelle Krikorian <gaelle.krikorian at gmail.com> wrote:
I bet $1,705 billion. They have at least to double the figure…
Le 14 nov. 2014 à 18:35, Jamie Love <james.love at keionline.org> a écrit :
> Next week, a new version of the Tufts study on R&D costs will be released.
> KEI will give $50 to the person who comes the closed in predicting the new
> figure for the cost of R&D for the lead indication of a new chemical entity.
> An abstract of the earlier 2003 study,"The price of innovation: new
> estimates of drug development costs" is available here:
> The 2003 study put the number at $802 million (not $800 million, but $802
> million), in 2000 dollars.
> As I said, $50 for the closest estimate, published on IP-Health, before the
> new number is announced (or leaked).
> James Love. Knowledge Ecology International
> KEI DC tel: +1.202.332.2670, US Mobile: +1.202.361.3040, Geneva Mobile:
> +41.76.413.6584, twitter.com/jamie_love
> Ip-health mailing list
> Ip-health at lists.keionline.org
galk at free.fr
Tel +33 (0)6 09 17 70 55
Ip-health mailing list
Ip-health at lists.keionline.org
More information about the Ip-health